Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS: Switching to Natalizumab in RRMS
NCT01058005Phase 3Terminated
- Sponsor
- Biogen
- Start
- Mar 2010
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Mar 2010; status: terminated.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01058005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01058005.